Effectiveness of SGLT2is vs. GLP-1RAs on cardiovascular and cerebrovascular outcomes in T2D patients according to CVD status

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. The comparative cardiovascular and renal effectiveness of sodium‐glucose co‐transporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists: A Scandinavian cohort study· 2021 · 31 citations
2. Comparative effectiveness of SGLT2i versus GLP1-RA on cardiovascular outcomes in routine clinical practice· 2022 · 32 citations
3. Comparative cardiovascular effectiveness of glucagon‐like peptide‐1 receptor agonists versus sodium‐glucose cotransporter‐2 inhibitors in patients with type 2 diabetes: A population‐based cohort study· 2022 · 23 citations
4. Sodium–Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease· 2021 · 100 citations
5. Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study· 2021 · 57 citations